A multidisciplinary team led by Associate Professor Mengyang Liu at the Center for Medical Physics and Biomedical Engineering, Medical University of Vienna, alongside Associate Professor Kristen Meiburger from Politecnico di Torino, have engineered a sophisticated OC-PAM platform specifically tailored for intricate 3D cancer models. By harnessing the complementary imaging capabilities of optical coherence microscopy (OCM) and photoacoustic microscopy (PAM), the researchers achieve label-free, volumetric visualization with remarkable spatial resolution and functional contrast. The integration of AI-driven analytics further empowers the system to perform comprehensive longitudinal tracking, viability assessments, and rare cell detection—capabilities that conventional imaging tools struggle to deliver without perturbation.

A key feat demonstrated by the OC-PAM system is its application to breast cancer organoids subjected to carboplatin chemotherapy. The use of OCM mode enabled high-resolution imaging of individual organoid structures over multiple time points, capturing dynamic volumetric changes associated with drug exposure. Automated algorithms tracked organoid morphology, revealing distinct growth trajectories that delineated responsive subpopulations from a resilient minority exhibiting regrowth—phenotypically consistent with drug-tolerant persister (DTP) cells. This ability to longitudinally monitor tumor heterogeneity and therapeutic resistance in a label-free setting represents a significant methodological leap.

Beyond morphological tracking, the research team introduced a radiomics-based framework that extracts high-dimensional quantitative features from OCM images. Paired with machine learning classifiers, this approach robustly discriminates viable from non-viable organoids without requiring invasive staining or fluorescence markers. The predictive accuracy achieved underscores the transformative potential of combining optical imaging with advanced computational analysis for continuous, non-destructive monitoring of treatment efficacy, a critical unmet need in preclinical oncology research.

The novel capabilities of the combined OC-PAM system extend to probing the cellular microenvironment within densely packed 3D spheroids, particularly the detection of rare cell populations. By co-culturing breast cancer cells with melanoma cells rich in melanin, the PAM component leveraged intrinsic optical absorption contrast to highlight these rare cell proxies amid the stromal milieu. Impressively, the system resolved individual melanoma cells even at extremely low concentrations, offering a sensitive platform for elucidating intratumoral heterogeneity and understanding the roles of minor subclones in cancer progression and drug resistance.

Central to the success of this approach is the synergy between OCM and PAM modalities. OCM provides label-free, volumetric imaging by exploiting the interference of backscattered near-infrared light, facilitating high axial and lateral resolution. Conversely, PAM transduces optically induced ultrasonic waves generated by transient thermoelastic expansion upon light absorption, revealing functional and molecular contrasts invisible to conventional microscopy. Their co-registration within the OC-PAM framework creates a comprehensive multimodal imaging channel that captures both structural and biochemical tumor attributes simultaneously.

The incorporation of AI-based analytics constitutes another pillar of this technological breakthrough. Leveraging convolutional neural networks and advanced radiomic feature extraction, the system automates organoid segmentation, classification, and viability scoring with minimal human intervention. This automated pipeline not only reduces observer bias but also accelerates data throughput, enhancing reproducibility and quantitative rigor for large-scale drug screening endeavors. It exemplifies the profound impact of integrating state-of-the-art optical hardware with computational intelligence in overcoming biological complexity.

Importantly, the ability to track drug-induced changes at the individual organoid level enhances the granularity of therapeutic assessment. Rather than summarizing responses across heterogeneous populations, this system reveals subtle variabilities within clonal populations, capturing early emergence of resistant phenotypes. Such insights are invaluable in informing adaptive therapy regimens and accelerating the identification of novel therapeutic targets specific to resistant cancer niches.

The researchers’ demonstration of non-invasive viability assessment further resonates with clinical aspirations for personalized medicine. By circumventing the need for destructive staining, the platform enables continuous, longitudinal studies on patient-derived organoids, potentially allowing on-demand evaluation of individualized drug responses. This capability aligns with the overarching goal of precision oncology to tailor treatment strategies based on dynamic tumor profiling rather than static, one-time biopsies.

Moreover, the success in detecting rare melanoma cells amidst breast cancer spheroids validates the platform’s application in modeling complex tumor-immune microenvironments and heterogeneous cell interactions. The exquisite sensitivity to minor cell subpopulations could catalyze studies on metastatic colonization, dormancy, and immune evasion—areas critical to unraveling cancer lethality mechanisms.

Taken together, this study establishes optical coherence photoacoustic microscopy combined with AI as a powerful imaging paradigm transcending traditional constraints. With its non-invasive, label-free, high-resolution, and functional imaging capabilities, along with robust computational analyses, OC-PAM is poised to revolutionize fundamental cancer biology research, drug development pipelines, and ultimately, precision oncology clinical workflows.

As translational researchers continue grappling with intratumor heterogeneity and therapeutic resistance, platforms like OC-PAM offer a glimpse into the future of cancer modeling—one where the dynamic interplay of cell populations can be visualized, quantified, and harnessed to devise more effective, personalized interventions. The fusion of cutting-edge optical technologies with AI analytics signals a new dawn in how complex cancer systems are interrogated and understood.

This technological breakthrough exemplifies how interdisciplinary convergence—melding optics, computational science, and cellular biology—can unlock new frontiers in biomedical imaging. The potential for scaling this approach, adapting it across diverse cancer types, and integrating functional assays positions OC-PAM as a cornerstone innovation in the fight against cancer.

In conclusion, the newly developed AI-enhanced optical coherence photoacoustic microscopy platform stands as a versatile, high-impact tool for the imaging and analysis of 3D cancer models. By overcoming the limitations of existing imaging methods, it enables unprecedented, label-free longitudinal studies of tumor organoids and spheroids. Such advancements promise to accelerate therapeutic discovery, illuminate mechanisms of drug resistance, and guide precision oncology with unparalleled resolution and depth.

Subject of Research: Optical coherence photoacoustic microscopy for imaging and AI-assisted analysis of 3D cancer organoids and spheroids.

Article Title: Optical coherence photoacoustic microscopy for 3D cancer model imaging with AI-assisted organoid analysis

Web References: DOI:10.1038/s41377-025-02177-2

Image Credits: Mengyang Liu et al.

Keywords: Optical coherence microscopy, photoacoustic microscopy, AI-assisted imaging, cancer organoids, spheroids, drug resistance, tumor heterogeneity, non-invasive imaging, longitudinal tracking, radiomics, drug-tolerant persister cells, melanoma cells detection

At the heart of this innovation lies holo-tomographic flow cytometry, a fusion of holographic microscopy and flow cytometry technologies. This hybrid approach harnesses the power of label-free, three-dimensional imaging while simultaneously maintaining the high-throughput capabilities necessary for analyzing large populations of cells. By marrying these techniques, the research team has surpassed conventional limitations, enabling detailed visualization of cellular morphology and dynamics directly linked to underlying genetic mutations.

The process begins with the interrogation of cellular blasts—immature cells often implicated in hematologic disorders and malignancies—under holo-tomographic conditions that reconstruct their three-dimensional refractive index distributions. These reconstructions provide quantitative biophysical information such as cell volume, intracellular density distributions, and nuclear-cytoplasmic ratios without resorting to fluorescent or chemical staining, which often alters cellular physiology or limits temporal resolution.

Conventional flow cytometry has long been relied upon for sorting and classifying cells based on surface markers and fluorescence-labeled antibodies. However, its inability to capture intrinsic cellular properties without exogenous labels presented a bottleneck in discerning subtle phenotypic consequences of mutations. By integrating holographic imaging, the method captures intrinsic optical properties of the cells, transforming the flow cytometer from a marker-dependent sorting tool to a comprehensive phenotypic decoder.

One of the study’s core achievements is the direct linking of genotype—specific mutation profiles—with distinct phenotypic fingerprints observed through the holo-tomographic readouts. Using advanced computational algorithms, the researchers decoded alterations in cellular refractive indices that correlated with particular mutations found in blast cells. Such precise phenotypic mapping opens avenues for swift and non-invasive diagnosis, stratification, and monitoring of diseases characterized by cellular mutations, especially cancers and blood disorders.

The implications extend far beyond diagnosis. Understanding how specific mutations alter cellular structure and behavior in real time fosters a granular view of disease progression and response to therapies. For instance, the ability to detect subtle changes in intracellular density distributions or nuclear morphology could predict cellular resistance to chemotherapy, enabling preemptive adjustments to treatment regimens tailored to individual patients.

Moreover, the technique’s label-free nature offers significant advantages for clinical applications. Avoiding fluorescent dyes or genetic tagging reduces cellular perturbations and toxicity, preserving the authentic phenotype. This facilitates longitudinal studies on the same cellular populations, crucial for monitoring dynamic changes in heterogeneous cell communities, such as cancer stem cells or immune cell subsets responding to immunotherapies.

The researchers also meticulously optimized the flow conditions and holographic reconstruction algorithms to ensure rapid data acquisition without compromising spatial resolution. This breakthrough allows processing of thousands of cells per minute, rivaling traditional flow cytometry throughput while adding the unprecedented dimension of holistic cellular morphology. Such scalability paves the way for implementation in clinical laboratories where swift turnaround times are essential.

From a technological standpoint, the integration demanded sophisticated hardware innovations. The flow cytometer was equipped with a coherent light source configured for digital holographic imaging, along with high-speed cameras capable of capturing interference patterns generated by flowing cells. State-of-the-art GPU-accelerated software reconstructed three-dimensional refractive indices in milliseconds, enabling real-time phenotypic assessments.

The successful decoding of mutations at the phenotype level also underscores the potential for machine learning models to further enhance cell classification. By training algorithms on the holo-tomographic datasets, it becomes feasible to detect otherwise imperceptible patterns predictive of mutational status, disease progression, or therapeutic outcomes. This synergy between optics and artificial intelligence embodies the future of precision diagnostics.

Importantly, the study’s methodology is not limited to blast cells. The platform’s versatility allows adaptation to a variety of cell types and states, encompassing stem cells, immune effectors, and circulating tumor cells. This universality suggests broad applicability across biomedical research and clinical diagnostics, potentially revolutionizing how cells are studied and categorized based solely on intrinsic physical properties.

Ethical considerations, too, have been addressed by maintaining non-destructive interrogation of live cells, facilitating downstream functional analyses or cultivation post-sorting. This preserves cell viability and functionality—a vital factor when dealing with scarce or precious clinical specimens, ensuring comprehensive characterization without compromising future experimental possibilities.

While the research signifies a leap forward, challenges remain in translating this technology to routine clinical workflows. Standardization of holographic reconstructions across diverse instruments and biological samples is essential to ensure reproducibility and reliability. Additionally, integrating the phenotypic data with genomic and proteomic information will require sophisticated data management strategies and interpretative frameworks.

Nevertheless, the envisioned future is compelling. Imagine a clinic where a simple blood draw undergoes holo-tomographic flow cytometry, instantly revealing mutational landscapes and phenotypic states that guide therapeutic decisions with unmatched precision. By converting genotype information into easily interpretable phenotypic signatures, clinicians could target therapies more effectively, reduce side effects, and enhance patient outcomes.

This study exemplifies the power of interdisciplinary innovation, blending optics, computational science, and cellular biology to confront one of the most intricate puzzles in life sciences. Its impact will resonate deeply within oncology, hematology, and regenerative medicine, paving the way for personalized, real-time cellular phenotyping that was previously inconceivable.

In conclusion, holo-tomographic flow cytometry marks a transformative milestone in decoding the complexities of cellular mutations and their phenotypic expressions. The method’s ability to analyze thousands of cells in a label-free, non-invasive manner while providing rich biophysical data sets a new paradigm in cellular diagnostics. As further refinements emerge and clinical validations proceed, this technology promises to reshape our approach to understanding and treating diseases rooted in genetic mutations.

The future glimpsed by this research is one where cellular phenotypes serve as transparent windows into the mutational mechanisms driving disease, observable in real time without disrupting cellular integrity. Such clarity will empower a new generation of precision medicine, informed by the subtle language of refractive indices and holographic images, ultimately revolutionizing patient care on a global scale.

Subject of Research: Decoding cellular mutations and linking genotype to phenotype using holo-tomographic flow cytometry.

Article Title: From genotype to phenotype: decoding mutations in blasts by holo-tomographic flow cytometry.

Article References:
Pirone, D., Di Natale, C., Di Summa, M. et al. From genotype to phenotype: decoding mutations in blasts by holo-tomographic flow cytometry. Light Sci Appl 14, 233 (2025). https://doi.org/10.1038/s41377-025-01913-y

Image Credits: AI Generated

DOI: https://doi.org/10.1038/s41377-025-01913-y